PRESENTATION TITLE
Successes and Failures in Drug Development in Pancreatic Cancer

PRESENTER(S)
Tanios Bekaii-Saab, M.D., FACP, Professor of Medicine, Leader of the Gastrointestinal Cancer Program, Director for the Clinical Cancer Research Office of the Enterprise-wide Mayo Clinic Cancer Center, Vice Chair and Section Chief for Medical Oncology, Mayo Clinic, Phoenix, Arizona

PRESENTER BIO

Tanios Bekaii-Saab, MD, FACP is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program and Director of the Clinical Cancer Research Office for the Enterprise-wide Mayo Clinic Cancer Center. He is also the Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona, USA. He is also the consortium chair for the ACCRU research Network and the clinical research co-lead for the MCCC transformation leadership team for the Mayo Enterprise. Additionally, Dr. Bekaii-Saab is the Mayo Clinic member for the NCCN Guidelines Steering Committee. Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Vice-Chair for the National Cancer Institute’s Hepatobiliary Task Force. He is also a member of the ASCO Scientific Program Committee for Colorectal and Anal Cancers. He was previously at the Ohio State University – Arthur G. James Cancer Hospital and Solove Research Institute as a tenured professor of Medicine and Pharmacy, and Section Chief for the Gastrointestinal Cancer Program.

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.

Dr.  Bekaii-Saab, MD, conducts clinical and translational research focused on developing anticancer agents for patients with gastrointestinal cancers. Dr. Bekaii-Saab collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. Bekaii-Saab’s research includes a large focus on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as the feeding microenvironment and the immune milieu. His work includes two recent discoveries as co-inventor of a molecule that targets cancer-related cachexia (AR-42) and an anti-PD-1 vaccine (PD-Vaxx), which has resulted in licensing opportunities (under patents: US6387883B1, EP3600389A1, WO2019055687A1, ES2729619T3 and others). AR42 was licensed to Recursion. PD-Vaxx was licensed to imugene and is undergoing clinical development in with the recent launch of IMU-201-101_"B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer". Additionally, Dr. Bekaii-Saab’s research has also led to the launch of a number of phase II and III clinical trials, including but not limited to a recent trial with a cancer stem cell inhibitor in pancreatic cancer, the development of an FGFR inhibitor in bile duct cancers including a contribution to the regulatory approval of infigratinib and pemigatinib. He also contributed to the pivotal study that led to the regulatory approval of nanoliposomal irinotecan for treating pancreatic cancer.

Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute.  Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

VIEWING LOCATIONS
Zoom Registration Link

LEARNING OBJECTIVES

• Assess the current treatment landscape in pancreatic cancer.
• Identify molecular targets in pancreatic cancer.
• Demonstrate future research opportunities in pancreatic cancer.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.